IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#1561
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$110M
Craig C. Parker
Surrozen, Inc. discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$SRZN Surrozen, Inc./DE | 53 | 38 | 29 | 85 | - | - | 1202.4% | -64.1% | 100.0% | -746.0% | -1500.7% | -90.2% | 0.0% | - | $110M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
Surrozen, Inc./DE (SRZN) receives a "Hold" rating with a composite score of 52.8/100. It ranks #1561 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Direct cash return
Craig C. Parker
Chief Executive Officer
Labor Force
80
38
36
51
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for SRZN
Outperforming peers — winners tend to keep winning over 3-12 months
Expensive relative to fundamentals — limited margin of safety
Average quality profile
Average volatility — neutral timing signal
Moderate investment profile
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for SRZN.
View All RatingsHigh margin volatility — erratic forensic earnings quality
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 38 | 15 | +23ALPHA |
| MOMENTUM | 85 | 89 | -4NEUTRAL |
| VALUATION | 29 | 11 | +18ALPHA |
| INVESTMENT | 36 | 59 | -23DRAG |
| STABILITY | 51 | 37 | +14ALPHA |
| SHORT INT | 57 | 65 | -8DRAG |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy 1202.4% (sector -2.5%)
GM 100% vs sector 43%, OM -746% vs sector 1%
Capital turnover N/A, R&D intensity 690.9%
Rev growth -90%, 5yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our model assigns Surrozen, Inc./DE a Hold rating, with a composite score of 52.8/100 and 3 out of 5 stars. Ranked #1561 of 7,333 stocks, SRZN presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
SRZN's quality score of 38/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of 1202.4% (sector avg: -2.5%), gross margins of 100.0% (sector avg: 42.5%), net margins of -1500.7% (sector avg: -0.2%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
SRZN registers a value score of just 29/100, suggesting the stock trades at a significant premium to its fundamental metrics. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
Surrozen, Inc./DE's investment score of 36/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of -90.2% vs. a sector average of 5.9% and a return on assets of -64.1% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
SRZN shows strong momentum characteristics with a score of 85/100. The stock has been trending above key moving averages, indicating solid demand from institutional buyers. Revenue growth stands at -90.2% year-over-year, while a beta of 0.54 reflects its sensitivity to broader market moves. This level of momentum typically signals sustained investor confidence and favorable near-term price action.
With a stability score of 51/100, SRZN exhibits average financial resilience. Key stability metrics include a beta of 0.54. While the balance sheet is not a major concern, the stock is subject to typical market volatility and may experience sharper drawdowns during risk-off episodes.
The short interest score of 57/100 for SRZN suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include micro-cap liquidity risk. With a $110M market cap (micro-cap), Surrozen, Inc./DE may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
Surrozen, Inc./DE is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #1561 of 7,333 overall (79th percentile). Key comparisons include ROE of 1202.4% exceeding the -2.5% sector median and operating margins of -746.0% below the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While SRZN currently exhibits a HOLD profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Key factor gap
Momentum (85) vs Value (29) — closing this gap could shift the rating.
ROE 48584% BELOW SECTOR MEDIAN
Gross Margin 135% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 57928% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate Surrozen, Inc./DE (SRZN) as a Hold with a composite score of 52.8/100 at a current price of $26.92. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling for existing holders. Our factors are split, and the overall profile suggests patience is warranted.
The rating is primarily driven by strength in momentum (85th percentile) and stability (51th percentile), which together account for the majority of the composite score. Offsetting weakness in value (29th percentile) and investment (36th percentile) tempers our overall conviction. We assign a Narrow Moat rating (44/100), Medium uncertainty, and Poor capital allocation.
Key items to watch: whether strong momentum is fundamentally supported by revenue trends; the path to profitability; valuation compression risk if growth disappoints. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
Surrozen, Inc./DE holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 52.8/100 places it at rank #1561 in our full 7,333-stock universe. At $110M in market capitalization, Surrozen, Inc./DE is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Despite positive momentum (85th percentile), revenue contraction of -90% creates a divergence between price action and fundamental trajectory. This divergence suggests either that the market is looking through near-term weakness or that technical factors are temporarily inflating the stock. Investors should assess whether the revenue decline reflects cyclical weakness or structural challenges.
The margin cascade tells an important story: gross margins of 100% (+57.5pp vs sector) narrow to operating margins of -746% (-747.3pp vs sector) and net margins of -1500.7%, yielding a gross-to-net conversion rate of -1501%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $26.92, Surrozen, Inc./DE is trading at a premium to fundamental value. Our value factor score of 29/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at P/S of 17.6x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
Gross margins of 100% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
Returns on equity of 1202.4% exceed the cost of equity for most companies, indicating genuine shareholder value creation and a reinvestment engine that compounds wealth over time.
Positive momentum (85th percentile) indicates institutional accumulation and favorable technical dynamics that tend to persist in the intermediate term.
Revenue decline of -90% signals business deterioration — declining revenues make it difficult to grow into the current valuation and often precede further negative revisions.
Thin net margins of -1500.7% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
We assign a Medium uncertainty rating to Surrozen, Inc./DE. The stock presents a balanced risk profile: current negative profitability (net margin -1500.7%) and low beta of 0.54 — while defensive, this may indicate limited upside participation in bull markets. While not risk-free, the core business fundamentals are adequate to withstand moderate economic stress, and the range of potential outcomes around our fair value estimate is manageable.
Specific risk factors that inform our assessment include: current negative profitability (net margin -1500.7%); low beta of 0.54 — while defensive, this may indicate limited upside participation in bull markets. Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 51th percentile and quality factor at the 38th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 100% provide a buffer against cost pressures. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile is favorable for long-term investors.
We rate Surrozen, Inc./DE's capital allocation as Poor. Key concerns include negative profitability, weak asset returns (ROA -64.1%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — Surrozen, Inc./DE significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, Surrozen, Inc./DE receives a Hold rating with a composite score of 52.8/100 (rank #1561 of 7,333). Our quantitative framework assigns a Narrow Moat (44/100, trend: stable), Medium uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 48/100.
Our analysis supports a neutral stance on Surrozen, Inc./DE. While the quantitative profile is not weak enough to warrant selling, it lacks the multi-factor strength required for a buy recommendation. Existing holders should maintain positions and monitor for catalysts — either fundamental improvement or valuation compression — that would shift the risk-reward balance.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We assign Surrozen, Inc./DE a Narrow Moat rating with a composite moat score of 44/100. The company possesses identifiable competitive advantages, though they are less entrenched than those of wide-moat peers. Our analysis indicates that Surrozen, Inc./DE can sustain above-average returns on invested capital for at least 10 years, with the strongest contributor being economic value creation at 17.5/20.
The strongest moat sources are economic value creation (17.5/20) and margin superiority (10.4/20). ROE proxy 1202.4% (sector -2.5%). GM 100% vs sector 43%, OM -746% vs sector 1%. These pillars form the core of Surrozen, Inc./DE's competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include financial resilience (2.5/20) and reinvestment efficiency (7/20). Interest coverage N/A. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect Surrozen, Inc./DE's moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 100% providing a solid profitability foundation, declining revenues (-90%) that pressure the earnings outlook, returns on equity of 1202.4% driving shareholder value creation. The margin cascade from 100% gross to -746% operating to -1500.7% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality raises some durability concerns, with the quality factor at the 38th percentile.
The margin profile shows gross margins of 100%, operating margins of -746%, net margins of -1500.7%. Return metrics include ROE of 1202.4% and ROA of -64.1%. Relative to the Manufacturing sector, gross margins are 57.5 percentage points above the sector median of 43%, and ROE of 1202.4% compares to a sector median of -2.5%.
The balance sheet reflects revenue growth of -90%. Overall balance sheet health is adequate for the current business environment.
Above 50MA
37.18%
Net New Highs
+51081
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that on February 17, 2026, Surrozen granted a non-statutory stock option for an aggregate of 3,070 shares of Surrozen common stock to a recently hired non-executive employee as
Surrozen (NASDAQ:SRZN) Chief Executive Officer Craig Parker used a discussion at a 2026 investor summit to outline the company’s focus on Wnt pathway biology and antibody engineering, with an emphasis on retinal vascular diseases. Parker said Surrozen has worked on Wnt signaling since its founding i
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference. Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 Presentation

Gainers Edible Garden AG Incorporated (NASDAQ: EDBL) shares jumped 58% to $1.88 after the company reported better-than-expected second-quarter financial results. Capri Holdings Limited (NYSE: CPRI) climbed 56.1% to $54.03 after Tapestry announced a definitive agreement to acquire the company. Blend Labs, Inc. (NYSE: BLND) rose 32% to $1.6198 following better-than-expected second-quarter results. Athersys, Inc. (NASDAQ: ATHX) gained 31% to $0.5783. Yellow Corporation (NASDAQ: YELL) climbed 30% to $2.21. Holley Inc. (NYSE: HLLY) surged 26% to $7.83 after the company posted upbeat second-quarter results and raised FY23 revenue outlook. WeWork Inc. (NYSE: WE) shares gained 21% to $0.1560. WeWork shares fell over 38% on Wednesday after the company reported worse-than-expected second-quarter financial results. LifeMD, Inc. (NASDAQ: LFMD) climbed 20% to $4.39 following strong quarterly results. YETI Holdings, Inc. (NYSE: YETI) climbed 19% to $47.08 after the company reported better-than-expected second-quarter adjusted EPS results and raised FY23 adjusted EPS and sales growth guidance. AppLovin Corporation (NASDAQ: APP) shares gained 19% to $34.97 after the company reported better-than-expected second-quarter results. Alarm.com Holdings, Inc. (NASDAQ: ALRM) climbed 18.8% to $58.48 after the company reported better-than-expected second-quarter financial results and issued guidance. CleanSpark, Inc. (NASDAQ: CLSK) rose 17.5% to $5.94 following a narrower-than-expected quarterly loss. CS Disco, Inc. (NYSE: LAW) gained 16.3% to $9.93 following strong quarterly results. Carrols Restaurant Group, Inc. (NASDAQ: TAST) gained 16% to $7.18 following strong quarterly results. Seneca Foods Corporation (NASDAQ: SENEA) jumped 15.4% to $47.45 following quarterly results. PHAXIAM Therapeutics S.A. (NASDAQ: PHXM) shares climbed 15.1% to $0.5020 after gaining 6% on Wednesday. Entravision Communications Corporation (NYSE: EVC) rose 14.7% to $4.2550. MacroGenics, Inc. (NASDAQ: MGNX) surged 14.4% to $5.70 after posting a profit for the second quarter. GoodRx Holdings, Inc. (NASDAQ: GDRX) rose 14.4% to $9.09. Bruush Oral Care Inc. (NASDAQ: BRSH) gained 14% to $4.85. Missfresh Limited (NASDAQ: MF) climbed 12.9% to $1.75. LiveRamp Holdings, Inc. (NASDAQ: RAMP) gained ...

Biotechnology company Surrozen reported a surprising Q2 2025 net income of $39.7 million, driven primarily by non-cash gains, while continuing to advance its ophthalmology pipeline focused on Wnt pathway modulation.